Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan; Center for Transfusion Medicine and Cell Therapy, Tokyo Medical and Dental University (TMDU) Hospital, Tokyo, Japan.
Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
Transpl Immunol. 2024 Oct;86:102093. doi: 10.1016/j.trim.2024.102093. Epub 2024 Jul 19.
Human adenovirus infection (HAdV) may be fatal in patients undergoing allogeneic hematopoietic cell transplantation (HCT). Cidofovir is effective in only a part of the post-HCT HAdV infection. Therefore, posttransplant immune reconstitution is important for HAdV clearance. We describe the detailed immune reconstitution and response of adenovirus-specific T cells in a patient with inborn errors of immunity who had disseminated HAdV infection with hepatitis post-HCT and was treated with cidofovir. Though the patient received cidofovir for only 19 days starting from Day 72 after HCT because of renal dysfunction, we observed T-cell reconstitution, a decrease in HAdV copy number, and amelioration of the symptoms of HAdV infection after Day 90. We initially observed expanded NK and CD8CD45RO memory subsets and later gradual increase of naïve T cells eveloped after cessation of cidofovir treatment. An increase in adenovirus-specific IFN-γ secretion from 2 to 4 months after HCT was confirmed by ELISpot assay. The progression of immune reconstitution and cidofovir treatment are considered to have contributed to survival in this patient. Optimization of transplantation methods, prompt appropriate antiviral medication, and virus-specific T-cell therapy would be necessary as the better strategy for systemic HAdV infection.
人腺病毒感染(HAdV)可能对接受异基因造血细胞移植(HCT)的患者致命。西多福韦仅对移植后 HAdV 感染的一部分有效。因此,移植后免疫重建对于清除 HAdV 很重要。我们描述了一名患有先天性免疫缺陷的患者在移植后发生弥漫性 HAdV 感染伴肝炎时的详细免疫重建和腺病毒特异性 T 细胞反应,该患者接受西多福韦治疗。尽管该患者由于肾功能障碍从移植后第 72 天开始仅接受了 19 天的西多福韦治疗,但我们观察到 T 细胞重建、HAdV 拷贝数减少和 HAdV 感染症状改善,这些都发生在第 90 天之后。我们最初观察到 NK 和 CD8CD45RO 记忆亚群的扩增,随后在停止西多福韦治疗后逐渐增加幼稚 T 细胞。ELISpot 检测证实,移植后 2 至 4 个月时,腺病毒特异性 IFN-γ分泌增加。免疫重建的进展和西多福韦的治疗被认为有助于该患者的存活。作为全身性 HAdV 感染的更好策略,需要优化移植方法、及时给予适当的抗病毒药物和病毒特异性 T 细胞治疗。